Når de to strata blev analyseret separat, var responsraterne i det stratum med tidligere proteasehæmmer- behandling numerisk lavere for de patienter, der skiftede til Atripla [92, 4% versus 94, 0% for PVR (sensitivitetsanalyse) for henholdsvis Atripla - og SBR- patienter (SBR, stayed on their baseline regimen); en forskel (95% CI) på - 1, 6% (- 10, 0%; 6, 7%)].
When the two strata were analysed separately, response rates in the stratum with prior PI-treatment were numerically lower for patients switched to Atripla [92.4% versus 94.0% for the PVR (sensitivity analysis) for Atripla and SBR patients respectively; a difference (95%CI) of -1.6% (-10.0%, 6.7%)].